Benjamin Liechty
Assistant Professor of Pathology and Laboratory Medicine
Make your next move.
Prepare your application
Review drafts before you send them.
Explore related searches
Articles (3)
Pituitary neuroendocrine tumors (PitNETs) are among the most common tumors encountered in neurooncology. While the majority of PitNETs demonstrate indolent behavior, a subset of tumors demonstrates aggressive behavior, including invasion into surrounding structures. As traditional imaging has limited capacity to distinguish tumor from post-operative changes, better methods of tumor delineation are needed to guide management. Somatotroph adenomas are known to express high levels of SSTR2, and SSTR2-targeting PET imaging has shown clinical utility in the management of neuroendocrine tumors and meningiomas. In this retrospective study of archival PitNETs (n = 271) and autopsy controls (AC) (n = 20), we show that although significant differences in SSTR2 immunostaining are appreciable between adenoma subtypes and ACs, high-staining cases are encountered in all subtypes. In ACs, females demonstrated significantly stronger SSTR2 staining than males. Weak age-related trends towards increasing labelling in females and decreasing labelling in males were noted but these did not reach statistical significance. Decreasing age-related trends were seen in gonadotrophs in both sexes; this was statistically significant in females. Our findings suggest that SSTR2-targeting imaging modalities may assist clinical management of a subset of PitNETs and that these results may need to be interpreted with consideration of patient age and sex.
Year:
2025
DNA methylation is an essential molecular assay for central nervous system (CNS) tumor diagnostics. While some fusions define specific brain tumors, others occur across many different diagnoses. We performed a retrospective analysis of 219 primary CNS tumors with whole genome DNA methylation and RNA next-generation sequencing. DNA methylation profiling results were compared with RNAseq detected gene fusions. We detected 105 rare fusions involving 31 driver genes, including 23 fusions previously not implicated in brain tumors. In addition, we identified 6 multi-fusion tumors. Rare fusions and multi-fusion events can impact the diagnostic accuracy of DNA methylation by decreasing confidence in the result, such as BRAF , RAF , or FGFR1 fusions, or result in a complete mismatch, such as NTRK, EWSR1, FGFR , and ALK fusions. Implications: DNA methylation signatures need to be interpreted in the context of pathology and discordant results warrant testing for novel and rare gene fusions.
Year:
2024
DNA methylation is an essential molecular assay for central nervous system (CNS) tumor diagnostics. While some fusions define specific brain tumors, others occur across many different diagnoses. We performed a retrospective analysis of 219 primary CNS tumors with whole genome DNA methylation and RNA next-generation sequencing. DNA methylation profiling results were compared with RNAseq detected gene fusions. We detected 105 rare fusions involving 31 driver genes, including 23 fusions previously not implicated in brain tumors. In addition, we identified 6 multi-fusion tumors. Rare fusions and multi-fusion events can impact the diagnostic accuracy of DNA methylation by decreasing confidence in the result, such as BRAF , RAF , or FGFR1 fusions, or result in a complete mismatch, such as NTRK, EWSR1, FGFR , and ALK fusions. Implications: DNA methylation signatures need to be interpreted in the context of pathology and discordant results warrant testing for novel and rare gene fusions.
Year:
2024
Collaborators (11)
David Pisapia
Assistant Professor
Weill Cornell Medicine
Matija Snuderl
Assistant Professor (Clinical) of Pathology
NYU School of Medicine
George Jour
Associate professor
NYU Langone Medical Center
Jeffrey Wisoff
Professor of Neurosurgery and Pediatrics
NYU School of Medicine
Tejus Bale
Assistant Attending L1
Memorial Sloan Kettering Cancer Center
Eveline Teresa Hidalgo
NYU Langone Health
Jeffrey Allen
Otto and Marguerite Manley and Making Headway Foundation Professor of Pediatric Neuro-Oncology and Professor (Clinical) of Neurology
NYU School of Medicine
david harter
NYU Langone Medical Center
Daniel Orringer
Associate Professor
NYU Langone Health
Theodore H. Schwartz
Professor
Icahn School of Medicine at Mount Sinai
Sharon L Gardner
Associate Professor (Clinical) of Pediatrics
NYU School of Medicine
Make your next move.
Prepare your application
Review drafts before you send them.